<img alt="" src="https://secure.wake4tidy.com/244317.png" style="display:none;">

Working together in the COVID-19 pandemic - our commitment and pledge

Vironova and industry working together in the COVID-19 pandemic

‘We are committed to helping the scientific community and biopharmaceutical industry in the fight against COVID-19 while maintaining the safety of our staff and the high-standard of our work’

We are all in the midst of an outbreak of COVID-19 caused by the novel coronavirus, SARS-CoV-2, and the impact on our normal daily lives has been profound. Researchers from the biopharmaceutical industry and academia around the world are in a race against time to gain a better understanding of this novel virus with the goal of rapidly identifying future treatment options and vaccine targets.

We believe that our experience in transmission electron microscopy (TEM)-based nanoparticle sample analysis (virus particles, viral vectors, VLPs, lipid nanoparticles, etc.) can greatly support  the efforts undertaken by the biopharmaceutical and research industry in their COVID-19 related work.

Vironova is committed to contributing with our technology and expertise in the mission of finding solutions to halt the pandemic. To focus our efforts, we have created a task force group of  in-house experts  dedicated to COVID-19 projects and we are currently involved in a range of research initiatives, hubs and consortia globally where we are offering our powerful and adaptable analysis methods. 

Coronavirus without scales

During this pandemic, our laboratories continue to operate under revised conditions in order to keep our staff safe whilst still providing our core laboratory services. Our non-laboratory-based personnel continue to work and offer support remotely.

Demonstrations of our microscopes and software are also being performed remotely. Should you have any problems in reaching your contact person at Vironova, please contact us on info@vironova.com

We appreciate your understanding for our new working conditions where the safety of our personnel and following the recommendations given by the Swedish public authorities is our priority. Nevertheless, we want to make sure that we are here to continue to offer our expertise and availability to discuss how we can help to analyze your samples to make sure that your product is optimally characterized and ready for clinical trials phases.

Contact Vironova´s Covid-19 Taskforce